COMMUNIQUÉS West-GlobeNewswire

NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024
21/11/2024
LANGHORNE, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
21/11/2024
Workshop, poster and oral presentation of data given as part of the 8 th Annual Antifibrotic Drug Development (AFDD) Summit Data demonstrate that NKT cells are activated in airways in IPF patients and inhibition of iNKT [...]
Cidara Therapeutics Announces $105 Million Private Placement
21/11/2024
Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors SAN DIEGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, [...]
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
21/11/2024
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global [...]
Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
21/11/2024
Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 138 [...]
Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
21/11/2024
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
FDA clears XENOVIEW® 3T Chest Coil in GE HealthCare MRI Systems
21/11/2024
Expands accessibility for institutions utilizing GE HealthCare MRI systems DURHAM, NC and LONDON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage [...]
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
21/11/2024
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices [...]
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
21/11/2024
Data to be presented at the 8 th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic potential compared to [...]
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors
21/11/2024
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf therapies that aim to realize the full reach and promise of CAR T-cells, today announced [...]
Acies Bio and Protein Evolution Announce Strategic Partnership to Advance Biological Recycling Technology
21/11/2024
LJUBLJANA, Slovenia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Protein Evolution , a pioneer in enzyme-driven plastics recycling, has announced a collaboration with Acies Bio , an innovative biotechnology company specializing [...]
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Revuforj® (revumenib)
20/11/2024
LOUISVILLE, Ky., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Syndax Pharmaceuticals for Revuforj ® (revumenib), [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/11/2024
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
20/11/2024
MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36 th Annual [...]
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
20/11/2024
Dr. Blackman’s departure planned for end of 2024 Company’s search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or [...]
Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas
20/11/2024
VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on [...]
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
20/11/2024
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc [...]
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
20/11/2024
VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic [...]
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
20/11/2024
Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced [...]

Pages